63 results
8-K
EX-99.3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
in a transaction that will bring OmniaAb to the public markets as a standalone company.
As healthcare investors, we are always searching for innovative … platform provides biopharma partners with access to diverse antibody repertoires and innovative high-throughput screening technologies to enable
425
EX-99.3
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
23 Mar 22
Business combination disclosure
5:29pm
in a transaction that will bring OmniaAb to the public markets as a standalone company.
As healthcare investors, we are always searching for innovative … platform provides biopharma partners with access to diverse antibody repertoires and innovative high-throughput screening technologies to enable
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
17 Sep 10
Ligand Enters into Agreement with Proximagen for CXCR4 Target
12:00am
novel
drugs and innovative new treatments for disorders of the central nervous system, bringing new hope to patients and value to its shareholders
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
5 Nov 12
Ligand Pharmaceuticals to Restate Previous Financial Statements
12:00am
innovative therapeutics, that results of any clinical study will be timely, favorable or confirmed by later studies, that products under development
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
22 May 14
Entry into a Material Definitive Agreement
12:00am
innovative therapeutics that improve patients’ lives. Viking has a portfolio of five drug candidates in clinical trials or preclinical studies, which
8-K
EX-99.1
1ndg8uf l7
2 Apr 20
Ligand Completes Acquisition of Icagen Core Assets, Partnered Programs
4:18pm
8-K
EX-99.1
gs4hd zf7
11 Oct 11
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
52a0ob8t46d0z
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
8-K
EX-99.1
aicth3lxuxn4xkojoc
25 Feb 03
Other events
12:00am
8-K
EX-99.1
ke7011ij
31 Jan 11
Ligand Forms Strategic Drug Development Alliance with Chiva Pharmaceuticals
12:00am
8-K
EX-99.1
jk5nur7e
6 Feb 20
Ligand Reports Fourth Quarter and Full Year 2019 Financial Results
4:05pm
8-K
EX-99.1
btez7n0bp8oaizoc
21 Dec 20
Ligand and GSK Enter Global Collaboration and License Agreement Leveraging Icagen’s Discovery Technology to Target Neurological Disorders
8:39am
8-K
EX-99.1
519i5ekkm nqt2k
5 Nov 12
Ligand Pharmaceuticals Reports Preliminary Third Quarter 2012 Results
12:00am
8-K
EX-99.1
hvjztq76ojju4n3h
31 Jul 08
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
8-K
EX-99.1
21n i8nk8iz95qtqw7
10 May 11
Ligand Pharmaceuticals Reports First Quarter Results
12:00am
8-K
hp8p1y
5 Mar 19
Entry into a Material Definitive Agreement
5:16pm
8-K
EX-99.1
m00ijx
2 May 12
Ligand Pharmaceuticals Reports First Quarter Results
12:00am
8-K
EX-99.1
epwjb
7 Feb 12
Ligand Reports Fourth Quarter and Full Year 2011 Financial Results
12:00am
8-K
EX-99.1
ag73dfezoz23crzajt
8 Aug 12
Ligand Pharmaceuticals Announces Second Quarter Results
12:00am
8-K
EX-99.1
1xkzh4awadih
8 Nov 11
Ligand Pharmaceuticals Announces Third Quarter Results
12:00am